PDCD1 and melanoma: Since PD-1 is mainly expressed by NCR+ ILC3s and inhibits cytokine secretion [73,74], it is possible that in ICI-treated melanoma patients, PD-1 blocking might unleash the inflammatory potential of ILC3s, which in turn contributes to the development of the psoriasis-like lesions observed in patients.